BACKGROUND: Cerebrospinal fluid (CSF) biomarkers have been increasingly studied in dementia clinical and differential diagnosis. METHODS: We assessed levels of total tau protein (tauT), tau phosphorylated at threonine 181 (tau P-181), and beta-amyloid1-42 (A beta 42) in 34 patients with frontotemporal lobar degeneration (FTLD), 76 Alzheimer disease (AD) cases, and 93 controls (CTRL). Double sandwich enzyme-linked immunosorbent assays (Innogenetics) were used for measurements. RESULTS: Total tau was significantly increased and A beta 42 decreased in FTLD and AD patients as compared with CTRL. CSF tau P-181 levels were significantly increased only in AD. The tauT/A beta 42 ratio successfully discriminated FTLD from CTRL with a 86.7% specificity and 80.6% sensitivity, whereas the tauT alone was more specific (95.7%) but less sensitive (64.75%). For the discrimination of FTLD from AD, tauT/A beta 42 ratio was better (90.3% sensitivity and 64.5% specificity) compared with the other biomarkers alone or in combination, whereas tau P-181 was less sensitive but more specific (68.4% and 85.7%, respectively). Subtype analysis revealed that the most AD-like profile of biomarkers were observed in FTLD with motor neuron signs, whereas the most non-AD profile were observed in patients with primary progressive aphasia. CONCLUSIONS: Combined analysis of CSF biomarkers may be useful for the best possible antemortem discrimination of FTLD from AD.
BACKGROUND: Cerebrospinal fluid (CSF) biomarkers have been increasingly studied in dementia clinical and differential diagnosis. METHODS: We assessed levels of total tau protein (tauT), tau phosphorylated at threonine 181 (tau P-181), and beta-amyloid1-42 (A beta 42) in 34 patients with frontotemporal lobar degeneration (FTLD), 76 Alzheimer disease (AD) cases, and 93 controls (CTRL). Double sandwich enzyme-linked immunosorbent assays (Innogenetics) were used for measurements. RESULTS: Total tau was significantly increased and A beta 42 decreased in FTLD and ADpatients as compared with CTRL. CSF tau P-181 levels were significantly increased only in AD. The tauT/A beta 42 ratio successfully discriminated FTLD from CTRL with a 86.7% specificity and 80.6% sensitivity, whereas the tauT alone was more specific (95.7%) but less sensitive (64.75%). For the discrimination of FTLD from AD, tauT/A beta 42 ratio was better (90.3% sensitivity and 64.5% specificity) compared with the other biomarkers alone or in combination, whereas tau P-181 was less sensitive but more specific (68.4% and 85.7%, respectively). Subtype analysis revealed that the most AD-like profile of biomarkers were observed in FTLD with motor neuron signs, whereas the most non-AD profile were observed in patients with primary progressive aphasia. CONCLUSIONS: Combined analysis of CSF biomarkers may be useful for the best possible antemortem discrimination of FTLD from AD.
Authors: C Liguori; A Romigi; N B Mercuri; M Nuccetelli; F Izzi; M Albanese; G Sancesario; A Martorana; G M Sancesario; S Bernardini; M G Marciani; F Placidi Journal: J Neurol Date: 2014-08-14 Impact factor: 4.849
Authors: David J Irwin; Corey T McMillan; Jon B Toledo; Steven E Arnold; Leslie M Shaw; Li-San Wang; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Murray Grossman Journal: Arch Neurol Date: 2012-08
Authors: Petra Steinacker; Corinna Hendrich; Anne-Dorte Sperfeld; Sarah Jesse; Stefan Lehnert; Alice Pabst; Christine A F von Arnim; Felix M Mottaghy; Ingo Uttner; Hayrettin Tumani; Albert Ludolph; Markus Otto Journal: J Neural Transm (Vienna) Date: 2009-08-01 Impact factor: 3.575
Authors: Joshua A Sonnen; Kathleen S Montine; Joseph F Quinn; Jeffrey A Kaye; John C S Breitner; Thomas J Montine Journal: Lancet Neurol Date: 2008-08 Impact factor: 44.182